The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
GSTP1 CpG island hypermethylation as a molecular biomarker for prostate cancer
Abstract
Somatic hypermethylation of CpG island sequences at GSTP1, the gene encoding the π‐class glutathione S‐transferase, appears to be characteristic of human prostatic carcinogenesis. To consider the potential utility of this epigenetic alteration as a biomarker for prostate cancer, we present here a comprehensive review of the literature describing somatic GSTP1 changes in DNA from prostate cells and tissues. GSTP1 CpG island hypermethylation has been detected in prostate cancer DNA using a variety of assay techniques, including (i) Southern blot analysis (SB), after treatment with 5‐m C‐sensitive restriction endonucleases, (ii) the polymerase chain reaction, following treatment with 5‐m C‐sensitive restriction endonucleases (RE‐PCR), (iii) bisulfite genomic sequencing (BGS), and (iv) bisulfite modification followed by the polymerase chain reaction, using primers selective for target sequences containing 5‐m C (MSP). In the majority of the case series so far reported, GSTP1 CpG island hypermethylation was present in DNA from at least 90% of prostate cancer cases. When analyses have been carefully conducted, GSTP1 CpG island hypermethylation has not been found in DNA from normal prostate tissues, or from benign prostatic hyperplasia (BPH) tissues, though GSTP1 CpG island hypermethylation changes have been detected in DNA from candidate prostate cancer precursor lesions proliferative inflammatory atrophy (PIA) and prostatic intraepithelial neoplasia (PIN). Using PCR methods, GSTP1 CpG island hypermethylation has also been detected in urine, ejaculate, and plasma from men with prostate cancer. GSTP1 CpG island hypermethylation, a somatic epigenetic alteration, appears poised to serve as a molecular biomarker useful for prostate cancer screening, detection, and diagnosis. © 2003 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
CpG-rich islands and the function of DNA methylation
Bird, A. P. (1986) · Nature · doi:10.1038/321209a0 · Cited by 3,777
Dinkova-Kostova, A. T., Holtzclaw, W. D., Cole, R. N., Itoh, K., Wakabayashi, N., Katoh, Y., Yamamoto, M., & Talalay, P. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.172398899 · Cited by 1,947
Cited by
Molecular genetics of prostate cancer: new prospects for old challenges
Shen, M. M., & Abate-Shen, C. (2010) · Genes & Development · doi:10.1101/gad.1965810 · Cited by 946
Targeting NRF2 signaling for cancer chemoprevention
Kwak, M.-K., & Kensler, T. W. (2010) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2009.08.028 · Cited by 305
Causes and consequences of DNA hypomethylation in human cancer
Hoffmann, M. J., & Schulz, W. A. (2005) · Biochemistry and Cell Biology · doi:10.1139/o05-036 · Cited by 252
Cancer Chemoprevention and Nutri-Epigenetics: State of the Art and Future Challenges
Gerhauser, C. (2012) · Topics in Current Chemistry · doi:10.1007/128_2012_360 · Cited by 194
Identification of a CpG Island Methylator Phenotype in Adrenocortical Carcinomas
Barreau, O., Assié, G., Wilmot-Roussel, H., Ragazzon, B., Baudry, C., Perlemoine, K., René-Corail, F., Bertagna, X., Dousset, B., Hamzaoui, N., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2993 · Cited by 132
Metadata
- Authors
- Nakayama, M., Gonzalgo, M. L., Yegnasubramanian, S., Lin, X., De Marzo, A. M., & Nelson, W. G.
- Venue
- Journal of Cellular Biochemistry
- Publisher
- Wiley
- Published
- 2003-12-15
- Volume
- 91
- Issue
- 3
- Pages
- 540-552
- ISSN
- 0730-2312 (ISSN-L)
- 1097-4644
- OpenAlex
- W1977422169
- Cited by
- 197
- References
- 2
- FWCI
- 3.11
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: GSTP1 CpG island hypermethylation as a molecular biomarker for prostate cancer. https://app.cochat.ai/papers/10.1002/jcb.10740
- The paper
- Nakayama, M., Gonzalgo, M. L., Yegnasubramanian, S., Lin, X., De Marzo, A. M., & Nelson, W. G. (2004). GSTP1 CpG island hypermethylation as a molecular biomarker for prostate cancer. Journal of Cellular Biochemistry. https://doi.org/10.1002/jcb.10740
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.